Items Tagged ‘renal cell cancer’

April 23, 2018

FDA Approves Opdivo plus Yervoy Combination for Advanced Kidney Cancer

By

CancerConnect News: The Food and Drug Administration granted approvals to Opdivo  (nivolumab) and Yervoy (ipilimumab) in combination for the treatment of intermediate or poor risk, previously untreated advanced kidney cancer (renal cell carcinoma). About Renal Cell Carcinoma Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, accounting for more than […]

View full entry

Tags: atezolizumab, Checkpoint inhibitors Keytruda, durvalumab, Imfinzi, kidney cancer, News, nivolumab, opdivo, pembrolizumab, Renal Cancer, renal cell cancer, Tecentriq


January 25, 2018

Breakthrough Therapy Designation Awarded by FDA for Lenvima and Keytruda Combination Treatment for Advanced Renal Cell Carcinoma

By

CancerConnect News: The U.S. Food and Drug Administration (FDA) has announced “Breakthrough Therapy Designation” for the multiple receptor tyrosine kinase inhibitor Lenvima® (lenvatinib) in combination with Keytruda® (pembrolizumab) for the potential treatment of patients with advanced renal cell carcinoma (RCC). About Renal Cell Carcinoma Each year in the United States, more than 61,000 people are […]

View full entry

Tags: immunotherapy, keytruda, lenvatinib, Lenvima, News, pembrolizumab, Precision Cancer Medicine, Renal Cancer, renal cell cancer


May 18, 2015

Inlyta®

By

Class: Biological Therapy Generic Name: axitinib Trade Name: Inlyta® For which conditions is this drug approved? Inlyta is approved for the treatment of advanced renal cell carcinoma (kidney cancer) when prior treatment hasn’t worked. What is the mechanism of action? Inlyta is a kinase inhibitor. These drugs work by blocking the action of enzymes called kinases, […]

View full entry

Tags: Biological Therapy, Drug Dictionary, I, Inlyta, kidney cancer, renal cell cancer